Ozempic, Wegovy and Zepbound get new FDA warning over rare condition

The FDA is requiring new warnings for GLP-1 drugs including Ozempic, Wegovy, Mounjaro and Zepbound over a potential increased risk of a rare eye condition that can cause permanent vision loss.

NewsBeagle is a discovery engine. We show the headline, a short source-supplied summary and clear attribution. The complete reporting remains with the publisher.